NUVB Nuvation Bio Inc.companySEC Filings & Insider Trading Activity 2026
Latest Nuvation Bio Inc. (NUVB) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 2, 2026, a 10-Q quarterly report filed on November 3, 2025, an 8-K current report filed on March 2, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Nuvation Bio Inc. (NUVB) (SEC CIK 1811063), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Global oncology focused on developing novel small molecule therapies for difficult-to-treat cancers, leveraging medicinal chemistry and clinical data
- • New emphasis: U.S. commercial launch of IBTROZI (taletrectinib) for ROS1+ NSCLC approved June 2025, plus new Eisai partnership for European and other territories in 2026
Risk Factors
- • Regulatory risk: FDA approval and post-approval obligations for IBTROZI (taletrectinib) granted June 11, 2025 for ROS1+ NSCLC treatment
- • Geopolitical risk: Commercial partnerships in Japan (NK) and China (Innovent) expose revenue to MHLW and NMPA regulatory environments
Management Discussion & Analysis
- • Revenue and profitability data not disclosed in MD&A section
- • No segment performance details provided
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New risk: FDA post-marketing regulatory requirements for IBTROZI since June 2025 approval, with potential penalties or product withdrawal for non-compliance
- • Updated commercial risk: Initiation of U.S. commercial launch of IBTROZI, highlighting risks in marketing, sales experience, and limited patient population estimates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 2025 earnings press release issued March 2, 2026 — full financials in Exhibit 99.1
- • Filing covers quarter ended December 31, 2025; no figures disclosed in this item directly
Annual Reports Archive10-K
AI-powered analysis of Nuvation Bio Inc. (NUVB) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Nuvation Bio Inc. (NUVB) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Nuvation Bio Inc. (NUVB) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $0 | $7.9M | $62.9M |
| Gross Profit | — | $0 | $795K | — |
| Operating Income | -$119.7M | -$99.8M | -$592.6M | -$213.1M |
| Net Income | — | -$75.8M | -$567.9M | -$204.6M |
| Gross Margin | — | — | 10.1% | — |
| Op. Margin | — | — | -7527.3% | -338.7% |
| Net Margin | — | — | -7213.8% | -325.3% |
| Balance Sheet | ||||
| Total Assets | $672.1M | $621.5M | $540.6M | $594.8M |
| Equity | $655.1M | $605.1M | $463.8M | $305.7M |
| ROE | — | -12.5% | -122.5% | -66.9% |
Source: XBRL financial data from Nuvation Bio Inc. (NUVB) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 2, 2026 | — | Analysis | — |
10-K | Mar 2, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 12, 2026 | — | — | |
8-K | Nov 26, 2025 | — | — | |
10-Q | Nov 3, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 7, 2025 | Mar 31, 2025 | — | |
10-K | Mar 6, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 5, 2024 | Jun 30, 2024 | — | |
10-Q | May 14, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Mar 15, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 10, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 12, 2021 | Jun 30, 2021 | — | |
10-Q | May 17, 2021 | Mar 31, 2021 | — | |
10-K | Mar 11, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 16, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest NUVB SEC filings in 2026?
Nuvation Bio Inc. (NUVB) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 3, 2025, an 8-K current report on March 2, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did NUVB file its most recent 10-K annual report?
Nuvation Bio Inc. (NUVB) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view NUVB 10-Q quarterly reports?
Nuvation Bio Inc. (NUVB)'s most recent 10-Q quarterly report was filed on November 3, 2025. SignalX displays every NUVB 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has NUVB filed recently?
Nuvation Bio Inc. (NUVB)'s most recent 8-K was filed on March 2, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find NUVB insider trading activity (Form 4)?
SignalX aggregates every NUVB Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does NUVB file with the SEC?
Nuvation Bio Inc. (NUVB) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new NUVB filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Nuvation Bio Inc. (NUVB).
What is NUVB's SEC CIK number?
Nuvation Bio Inc. (NUVB)'s SEC CIK (Central Index Key) number is 1811063. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1811063 to look up all NUVB filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find NUVB return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Nuvation Bio Inc. (NUVB) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Nuvation Bio Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 26+ filings.